Qiagen logged a 0.4% change during today's afternoon session, and is now trading at a price of $41.29 per share. The S&P 500 index moved 0.0%. QGEN's trading volume is 582,493 compared to the stock's average volume of 1,260,934.
Qiagen trades -12.56% away from its average analyst target price of $47.22 per share. The 15 analysts following the stock have set target prices ranging from $42.0 to $60.0, and on average have given Qiagen a rating of buy.
Anyone interested in buying QGEN should be aware of the facts below:
-
Qiagen's current price is 64.4% above its Graham number of $25.11, which implies that at its current valuation it does not offer a margin of safety
-
Qiagen has moved -17.0% over the last year, and the S&P 500 logged a change of 13.0%
-
Based on its trailing earnings per share of 1.45, Qiagen has a trailing 12 month Price to Earnings (P/E) ratio of 28.5 while the S&P 500 average is 15.97
-
QGEN has a forward P/E ratio of 19.5 based on its forward 12 month price to earnings (EPS) of $2.12 per share
-
The company has a price to earnings growth (PEG) ratio of 12.2 — a number near or below 1 signifying that Qiagen is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 2.55 compared to its sector average of 4.16
-
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide.
-
Based in Venlo, the company has 6,000 full time employees and a market cap of $9.42 Billion.